E-mail: jp.levesque@mater.uq.edu.au Received 15 July 2014; Revised 28 November 2014; Accepted 18 December 2014 Accepted article preview online 12 January 2015; Advance online publication 3 February 2015 Many patients with hematological neoplasms fail to mobilize sufficient numbers of hematopoietic stem cells in response to granulocyte colony-stimulating factor precluding subsequent autologous HSC transplantation. Plerixafor, a specific antagonist of the chemokine receptor CXCR4, can rescue some but not all patients who failed to mobilize with G-CSF alone.
